Clascoterone is a topical anti-androgen developed to treat androgenetic alopecia. Applied as a solution to the scalp, it blocks the binding of DHT to follicular receptors, without impacting overall hormonal balance.
Developed by Cosmo Pharmaceuticals (Switzerland), the molecule is currently undergoing regulatory review (FDA/EMA approval expected 2027-2028). Phase III clinical trials have shown an improvement in hair count of up to 539% compared to placebo. Clascoterone is not yet available in Swiss pharmacies.
Do you suffer from androgenetic alopecia and want a topical treatment, without oral intake, without affecting your hormonal balance? Have you stopped taking finasteride due to side effects?
The Croix d'Or Hair Clinic in Geneva provides information on clascoterone and guides you towards the solution best suited to your current situation.
Get your diagnosis online or contact us directly.
Clascoterone is a topical androgen receptor antagonist. For baldness, it is marketed under the brand name Breezula, in a 5% solution. It has been FDA-approved since 2020 under the name Winlevi (1%) for hormonal acne: its systemic safety profile is therefore well-documented.
In androgenetic alopecia, DHT binds to receptors in hair follicles and triggers their progressive miniaturization. Clascoterone blocks this binding directly at the follicle level, without reducing circulating DHT. The product acts where it is applied, with virtually no systemic absorption.
Are you interested in discussing your treatment options? Schedule an appointment with one of our specialist physicians: only a personalized examination can determine the best strategy for your situation. Treatment and follow-up are always tailored to your individual needs.
The pivotal SCALP-1 and SCALP-2 studies, conducted on 1,465 patients, evaluated clascoterone 5% solution against placebo for 6 months. In SCALP-1, the improvement in hair count in the target area reached up to +539% compared to placebo; in SCALP-2, this improvement was +168%.
No systemic hormonal impact was detected in either study. These figures are from randomized controlled trials and do not constitute a guarantee of individual results.
Note: The combination of clascoterone and minoxidil may potentiate the effects of both treatments. Data on this combination are currently being evaluated.
Clascoterone is indicated for patients with early to moderate androgenetic alopecia (Hamilton-Norwood I to IV), and in particular:
In women, DHT also plays a role in androgenetic alopecia. Data specific to the female population are currently being evaluated.
Clascoterone for baldness is not yet available in pharmacies or by prescription in Switzerland. Marketing authorization applications will be submitted to the FDA and EMA after the current 12-month safety observation period. Swissmedic generally follows the EMA's recommendations for new molecules; approval in Switzerland is expected within the same timeframe, 2027-2028.
The Croix d'Or Hair Clinic does not yet offer this treatment, but will assist you with information and preparation for your treatment.
The effects reported in the studies are local and benign:
No sexual or hormonal side effects have been detected. Definitive contraindications will be specified at the time of marketing authorization. For women of childbearing age, caution is still advised pending complete regulatory data.
Make an appointment today for personalized and high-quality aesthetic care. Our team of experts is here to offer you innovative treatments tailored to your needs.
Please select all the means by which you would like to receive information from the Clinique de la Croix d'Or:
You can unsubscribe at any time by clicking the link in the footer of our emails. For more information about our privacy practices, please review the privacy policy on our website.
We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices